177 related articles for article (PubMed ID: 35326730)
1. MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy.
Heugenhauser J; Galijasevic M; Mangesius S; Goebel G; Buchroithner J; Erhart F; Pichler J; Widhalm G; Stockhammer G; Iglseder S; Freyschlag CF; Oberndorfer S; Bordihn K; von Campe G; Czech T; Surböck B; Urbanic Purkart T; Marosi C; Felzmann T; Nowosielski M
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326730
[TBL] [Abstract][Full Text] [Related]
2. Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma.
Ellingson BM; Sampson J; Achrol AS; Aghi MK; Bankiewicz K; Wang C; Bexon M; Brem S; Brenner A; Chowdhary S; Floyd JR; Han S; Kesari S; Randazzo D; Vogelbaum MA; Vrionis F; Zabek M; Butowski N; Coello M; Merchant N; Merchant F
Clin Cancer Res; 2021 Jul; 27(14):3916-3925. PubMed ID: 33863808
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
Youssef G; Rahman R; Bay C; Wang W; Lim-Fat MJ; Arnaout O; Bi WL; Cagney DN; Chang YS; Cloughesy TF; DeSalvo M; Ellingson BM; Flood TF; Gerstner ER; Gonzalez Castro LN; Guenette JP; Kim AE; Lee EQ; McFaline-Figueroa JR; Potter CA; Reardon DA; Huang RY; Wen PY
J Clin Oncol; 2023 Jun; 41(17):3160-3171. PubMed ID: 37027809
[TBL] [Abstract][Full Text] [Related]
4. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
[TBL] [Abstract][Full Text] [Related]
5. Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Zeyen T; Paech D; Weller J; Schäfer N; Tzaridis T; Duffy C; Nitsch L; Schneider M; Potthoff AL; Steinbach JP; Hau P; Schlegel U; Seidel C; Krex D; Grauer O; Goldbrunner R; Zeiner PS; Tabatabai G; Galldiks N; Stummer W; Hattingen E; Glas M; Radbruch A; Herrlinger U; Schaub C
J Neurooncol; 2023 Sep; 164(3):607-616. PubMed ID: 37728779
[TBL] [Abstract][Full Text] [Related]
6. Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model.
de Godoy LL; Chawla S; Brem S; Wang S; O'Rourke DM; Nasrallah MP; Desai A; Loevner LA; Liau LM; Mohan S
J Neurooncol; 2023 May; 163(1):173-183. PubMed ID: 37129737
[TBL] [Abstract][Full Text] [Related]
7. A Comparative Retrospective Study of Immunotherapy RANO
Chen X; Lim-Fat MJ; Qin L; Li A; Bryant A; Bay CP; Gao L; Miskin N; Liu Z; Iorgulescu JB; Xu X; Reardon DA; Young GS
Front Oncol; 2021; 11():679331. PubMed ID: 34249718
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria.
Roh YH; Park JE; Kang S; Yoon S; Kim SW; Kim HS
Cancer Imaging; 2023 Oct; 23(1):102. PubMed ID: 37875970
[TBL] [Abstract][Full Text] [Related]
9. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.
Wen PY; van den Bent M; Youssef G; Cloughesy TF; Ellingson BM; Weller M; Galanis E; Barboriak DP; de Groot J; Gilbert MR; Huang R; Lassman AB; Mehta M; Molinaro AM; Preusser M; Rahman R; Shankar LK; Stupp R; Villanueva-Meyer JE; Wick W; Macdonald DR; Reardon DA; Vogelbaum MA; Chang SM
J Clin Oncol; 2023 Nov; 41(33):5187-5199. PubMed ID: 37774317
[TBL] [Abstract][Full Text] [Related]
10. Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial.
Buchroithner J; Erhart F; Pichler J; Widhalm G; Preusser M; Stockhammer G; Nowosielski M; Iglseder S; Freyschlag CF; Oberndorfer S; Bordihn K; von Campe G; Hoffermann M; Ruckser R; Rössler K; Spiegl-Kreinecker S; Fischer MB; Czech T; Visus C; Krumpl G; Felzmann T; Marosi C
Cancers (Basel); 2018 Oct; 10(10):. PubMed ID: 30301187
[TBL] [Abstract][Full Text] [Related]
11. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
Erhart F; Buchroithner J; Reitermaier R; Fischhuber K; Klingenbrunner S; Sloma I; Hibsh D; Kozol R; Efroni S; Ricken G; Wöhrer A; Haberler C; Hainfellner J; Krumpl G; Felzmann T; Dohnal AM; Marosi C; Visus C
Acta Neuropathol Commun; 2018 Dec; 6(1):135. PubMed ID: 30518425
[TBL] [Abstract][Full Text] [Related]
12. Parametric Response Mapping of FLAIR MRI Provides an Early Indication of Progression Risk in Glioblastoma.
Hoff BA; Lemasson B; Chenevert TL; Luker GD; Tsien CI; Amouzandeh G; Johnson TD; Ross BD
Acad Radiol; 2021 Dec; 28(12):1711-1720. PubMed ID: 32928633
[TBL] [Abstract][Full Text] [Related]
13. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.
Han K; Ren M; Wick W; Abrey L; Das A; Jin J; Reardon DA
Neuro Oncol; 2014 May; 16(5):696-706. PubMed ID: 24335699
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of pseudoprogression in patients with glioblastoma.
Kucharczyk MJ; Parpia S; Whitton A; Greenspoon JN
Neurooncol Pract; 2017 Jun; 4(2):120-134. PubMed ID: 31386017
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
[TBL] [Abstract][Full Text] [Related]
17. Early Pseudoprogression following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation.
Linhares P; Carvalho B; Figueiredo R; Reis RM; Vaz R
J Oncol; 2013; 2013():690585. PubMed ID: 24000284
[TBL] [Abstract][Full Text] [Related]
18. Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence?
Olivier T; Migliorini D
Rev Neurol (Paris); 2023 Jun; 179(5):502-505. PubMed ID: 37012085
[TBL] [Abstract][Full Text] [Related]
19. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
Front Immunol; 2018; 9():727. PubMed ID: 29910795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
